Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 567

1.

Changes over time in Uric Acid in relation to Changes in Insulin Sensitivity, Beta-cell Function, and Glycemia.

Volpe A, Ye C, Hanley AJ, Connelly PW, Zinman B, Retnakaran R.

J Clin Endocrinol Metab. 2019 Nov 13. pii: dgz199. doi: 10.1210/clinem/dgz199. [Epub ahead of print]

PMID:
31720687
2.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.

Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW.

Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044359. [Epub ahead of print]

PMID:
31707795
3.

Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease.

Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, Teoh H, Leiter LA, Zinman B, Jüni P, Zuo F, Mistry N, Thorpe KE, Goldenberg RM, Yan AT, Connelly KA, Verma S.

Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044235. [Epub ahead of print]

PMID:
31707794
4.

The macrophage activation marker soluble CD163 is longitudinally associated with insulin sensitivity and β-cell function.

Semnani-Azad Z, Connelly PW, Johnston LW, Retnakaran R, Harris SB, Zinman B, Hanley AJ.

J Clin Endocrinol Metab. 2019 Nov 1. pii: dgz166. doi: 10.1210/clinem/dgz166. [Epub ahead of print]

PMID:
31677389
5.

Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11).

Amod A, Buse JB, McGuire DK, Pieber TR, Pop-Busui R, Pratley RE, Zinman B, Hansen MB, Jia T, Mark T, Poulter NR; DEVOTE Study Group.

Diabetes Ther. 2019 Oct 30. doi: 10.1007/s13300-019-00715-x. [Epub ahead of print]

PMID:
31667706
6.

Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction.

Retnakaran R, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B.

J Am Heart Assoc. 2019 Nov 5;8(21):e014231. doi: 10.1161/JAHA.119.014231. Epub 2019 Oct 28.

7.

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.

Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, Kiš SG, Kaspers S, George JT, Fitchett D.

Age Ageing. 2019 Nov 1;48(6):859-866. doi: 10.1093/ageing/afz096.

PMID:
31579904
8.

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N; CAROLINA Investigators.

JAMA. 2019 Sep 19. doi: 10.1001/jama.2019.13772. [Epub ahead of print]

PMID:
31536101
9.

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators.

Diabetes Care. 2019 Sep 17. pii: dc190898. doi: 10.2337/dc19-0898. [Epub ahead of print]

PMID:
31530667
10.

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.

Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, Zinman B, Johansen OE.

Eur Heart J. 2019 Aug 31. pii: ehz621. doi: 10.1093/eurheartj/ehz621. [Epub ahead of print]

PMID:
31504427
11.

SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.

Hess DA, Terenzi DC, Trac JZ, Quan A, Mason T, Al-Omran M, Bhatt DL, Dhingra N, Rotstein OD, Leiter LA, Zinman B, Sabongui S, Yan AT, Teoh H, Mazer CD, Connelly KA, Verma S.

Cell Metab. 2019 Oct 1;30(4):609-613. doi: 10.1016/j.cmet.2019.08.015. Epub 2019 Aug 30.

PMID:
31477497
12.

Serum Ferritin and Glucose Homeostasis in Women With Recent Gestational Diabetes.

Hershenfeld S, Ye C, Hanley AJ, Connelly PW, Zinman B, Retnakaran R.

Can J Diabetes. 2019 Jun 21. pii: S1499-2671(19)30134-0. doi: 10.1016/j.jcjd.2019.06.003. [Epub ahead of print]

PMID:
31439472
13.

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA; EMPA-HEART CardioLink-6 Investigators.

Circulation. 2019 Aug 22. doi: 10.1161/CIRCULATIONAHA.119.042375. [Epub ahead of print]

PMID:
31434508
14.

The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort.

Santaren ID, Bazinet RP, Liu Z, Johnston LW, Sievenpiper JL, Giacca A, Retnakaran R, Harris SB, Zinman B, Hanley AJ.

Lipids. 2019 Oct;54(10):617-627. doi: 10.1002/lipd.12185. Epub 2019 Aug 19.

PMID:
31429083
15.

Serum apoA1 (Apolipoprotein A-1), Insulin Resistance, and the Risk of Gestational Diabetes Mellitus in Human Pregnancy-Brief Report.

Retnakaran R, Ye C, Connelly PW, Hanley AJ, Sermer M, Zinman B.

Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2192-2197. doi: 10.1161/ATVBAHA.119.313195. Epub 2019 Aug 15.

PMID:
31412738
16.

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.

Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A, Schnaidt S, Johansen OE; CARMELINA Investigators.

Diabetes Care. 2019 Oct;42(10):1930-1938. doi: 10.2337/dc19-0783. Epub 2019 Aug 9.

PMID:
31399442
17.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

18.

Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.

Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7.

19.

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, Koitka-Weber A.

Am J Kidney Dis. 2019 Nov;74(5):713-715. doi: 10.1053/j.ajkd.2019.03.432. Epub 2019 Jun 27. No abstract available.

PMID:
31255334
20.

Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.

Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B.

Diabetes Obes Metab. 2019 Oct;21(10):2192-2202. doi: 10.1111/dom.13811. Epub 2019 Jun 30. Review.

PMID:
31183975
21.

INTERMITTENT INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES: EFFECTS ON HYPOGLYCEMIA, WEIGHT GAIN, AND QUALITY OF LIFE OVER 2 YEARS.

Emery A, Ye C, Choi H, Kramer CK, Zinman B, Retnakaran R.

Endocr Pract. 2019 Sep;25(9):899-907. doi: 10.4158/EP-2019-0111. Epub 2019 Jun 6.

PMID:
31170361
22.

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C.

Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.

PMID:
31163986
23.

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.

Kidney Int. 2019 Aug;96(2):489-504. doi: 10.1016/j.kint.2019.02.033. Epub 2019 Mar 21.

PMID:
31142441
24.

Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience.

Molitch ME, Gao X, Bebu I, de Boer IH, Lachin J, Paterson A, Perkins B, Saenger AK, Steffes M, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):854-861. doi: 10.2215/CJN.14831218. Epub 2019 May 23.

PMID:
31123181
25.

Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes.

Groeneveld ON, van den Berg E, Johansen OE, Schnaidt S, Hermansson K, Zinman B, Espeland MA, Biessels GJ.

Diab Vasc Dis Res. 2019 Nov;16(6):577-581. doi: 10.1177/1479164119848093. Epub 2019 May 9.

PMID:
31068001
26.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

27.

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallén N, Luckevich M, Tutkunkardas D, Zinman B; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1706-1714. doi: 10.1111/dom.13730. Epub 2019 Apr 14.

28.

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.

Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782. doi: 10.1016/j.jacc.2019.03.002. Epub 2019 Mar 15. No abstract available.

PMID:
30885684
29.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
30.

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB.

Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2.

31.

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15.

32.

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A.

Lancet Diabetes Endocrinol. 2019 May;7(5):356-367. doi: 10.1016/S2213-8587(19)30066-X. Epub 2019 Mar 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Mar 11;:. Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20. Lancet Diabetes Endocrinol. 2019 Nov;7(11):e22.

PMID:
30833170
33.

HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy.

Janssen J, van den Berg E, Zinman B, Espeland MA, Geijselaers SLC, Mattheus M, Johansen OE, Biessels GJ.

Diabetes Care. 2019 Jan;42(1):e1-e3. doi: 10.2337/DC18-0914. No abstract available.

PMID:
30811335
34.

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jun;21(6):1437-1444. doi: 10.1111/dom.13677. Epub 2019 Apr 1.

35.

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.

Inzucchi SE, Wanner C, Hehnke U, Zwiener I, Kaspers S, Clark D, George JT, Zinman B.

Diabetes Care. 2019 Apr;42(4):e53-e55. doi: 10.2337/dc18-1355. Epub 2019 Jan 31. No abstract available.

PMID:
30705060
36.

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.

Verma S, Mazer CD, Bhatt DL, Raj SR, Yan AT, Verma A, Ferrannini E, Simons G, Lee J, Zinman B, George JT, Fitchett D.

Diabetes Care. 2019 Mar;42(3):e42-e44. doi: 10.2337/dc18-1959. Epub 2019 Jan 23. No abstract available.

PMID:
30674547
37.

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.

Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.

38.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
39.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP.

Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.

PMID:
30566004
40.

Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes.

Nunez Lopez YO, Retnakaran R, Zinman B, Pratley RE, Seyhan AA.

Mol Metab. 2019 Feb;20:63-78. doi: 10.1016/j.molmet.2018.11.003. Epub 2018 Nov 16.

41.

HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy.

Janssen J, van den Berg E, Zinman B, Espeland MA, Geijselaers SLC, Mattheus M, Johansen OE, Biessels GJ.

Diabetes Care. 2018 Nov 19. pii: dc180914. doi: 10.2337/dc18-0914. [Epub ahead of print] No abstract available.

PMID:
30455337
42.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

43.

Liraglutide and Glycaemic Outcomes in the LEADER Trial.

Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.

44.

Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A.

Diabetes Obes Metab. 2019 Mar;21(3):622-630. doi: 10.1111/dom.13565. Epub 2018 Nov 26.

45.

Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".

Wanner C, von Eynatten M, Zinman B.

Circulation. 2018 Aug 21;138(8):850-851. doi: 10.1161/CIRCULATIONAHA.118.035881. No abstract available.

PMID:
30359123
46.

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B.

Circulation. 2018 Oct 23;138(17):1904-1907. doi: 10.1161/CIRCULATIONAHA.118.035759. No abstract available.

PMID:
30354665
47.

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.

Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, Nauck M, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL.

Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862. No abstract available.

PMID:
30354517
48.

Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.

Claggett B, Lachin JM, Hantel S, Fitchett D, Inzucchi SE, Woerle HJ, George JT, Zinman B.

Circulation. 2018 Oct 9;138(15):1599-1601. doi: 10.1161/CIRCULATIONAHA.118.033810. No abstract available.

PMID:
30354516
49.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

50.

Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes.

Mehmood S, Ye C, Connelly PW, Hanley AJ, Zinman B, Retnakaran R.

Cardiovasc Diabetol. 2018 Oct 9;17(1):133. doi: 10.1186/s12933-018-0776-y.

Supplemental Content

Loading ...
Support Center